semaglutide weight loss creve coeur and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study Semaglutide cardiovascular outcomes align more

Some of our patients have experienced more substantial weight loss, while others have seen less of a difference

Addressing these fundamental questions of mechanism, delivery, and rigorous clinical validation will determine whether this remarkably versatile class of drugs can become a new pillar in the ophthalmologists armamentarium

Retatrutide is still in the architectural plans phase

Who Should Use Henry Meds Henry Meds is a good fit if you: Want compounded GLP-1 medications at competitive prices without insurance Prefer a fully online process with a live video provider consultation Want multiple medication formats (injectable and oral) Value bundled pricing with no separate membership or consultation fees Are comfortable with the trade-offs of compounded (non-FDA-approved) formulations Have read the trust analysis above and accept the documented risks Henry Meds is not ideal if you: Need insurance to cover your GLP-1 medication (try Found or Ro instead) Want brand-name Wegovy, Mounjaro, or Zepbound specifically Prioritize a perfect trust record and cannot tolerate the BBB F rating and active lawsuit Need structured behavioral coaching alongside medication Want transparent pharmacy disclosure upfront without having to ask Require easy self-service cancellation The platform serves a specific patient: someone who wants affordable, convenient access to compounded GLP-1 medications, is paying cash, understands the regulatory uncertainty around compounding in 2026, and is willing to be proactive about verifying pharmacy credentials and medication quality

Spread the word Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 24 trials (Phase 1 trials often pay substantially more)

Our guide to the difference between tirzepatide and retatrutide covers how the addition of glucagon receptor agonism changes the metabolic and longevity profile